[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100610498":3},{"organization":4,"armGroups":7,"interventions":23,"overallOfficials":29,"centralContacts":42,"locations":48,"responsibleParty":186,"collaborators":29,"id":188,"slug":189,"hasResults":190,"nctId":191,"briefTitle":192,"officialTitle":193,"acronym":194,"eligibilityCriteria":195,"healthyVolunteers":190,"sex":196,"minAge":197,"maxAge":198,"enrollmentInfo":199,"targetDuration":29,"studyType":202,"phases":203,"briefSummary":205,"conditions":206,"keywords":29,"overallStatus":73,"whyStopped":29,"lastUpdateSubmitDate":208,"lastUpdatePostDateStruct":209,"startDateStruct":212,"completionDateStruct":214,"leadSponsor":216,"locationsCount":217},{"fullName":5,"class":6},"AstraZeneca","INDUSTRY",[8,15,18],{"label":9,"type":10,"description":11,"interventionNames":12},"Part A - Cohort A1","EXPERIMENTAL","Participants will receive 4 doses of AZD1613 or placebo on days 1, 29, 57 and 85.",[13,14],"Drug: AZD1613 - Part A","Drug: Placebo - Part A",{"label":16,"type":10,"description":11,"interventionNames":17},"Part A - Cohort A2",[13,14],{"label":19,"type":10,"description":11,"interventionNames":20},"Part B - Chinese Cohort",[13,21,22],"Drug: AZD1613 - Part B","Drug: Placebo - Part B",[24,30,34,38],{"type":25,"name":26,"description":27,"armGroupLabels":28,"otherNames":29},"DRUG","AZD1613 - Part A","Part A - Participants will be administered doses of AZD1613 on days 1, 29, 57, and 85 according to randomization in IRT.",[9,16,19],null,{"type":25,"name":31,"description":32,"armGroupLabels":33,"otherNames":29},"Placebo - Part A","Part A - Participants will be administered doses of placebo on days 1, 29, 57, and 85 according to randomization in IRT.",[9,16],{"type":25,"name":35,"description":36,"armGroupLabels":37,"otherNames":29},"AZD1613 - Part B","Part B - Participants will be administered doses of AZD1613 on days 1, 29, 57, and 85 according to randomization in IRT.",[19],{"type":25,"name":39,"description":40,"armGroupLabels":41,"otherNames":29},"Placebo - Part B","Part B - Participants will be administered doses of placebo on days 1, 29, 57, and 85 according to randomization in IRT.",[19],[43],{"name":44,"role":45,"phone":46,"phoneExt":29,"email":47},"AstraZeneca Clinical Study Information Center","CONTACT","1-877-240-9479","information.center@astrazeneca.com",[49,63,72,82,90,99,108,117,126,136,144,152,160,168,176],{"facility":50,"status":51,"city":52,"state":53,"zip":54,"country":55,"countryCode":56,"cosmosGeoPoint":57,"geoPoint":62,"contacts":29},"Research Site","NOT_YET_RECRUITING","Birmingham","Alabama","35233","United States","US",{"type":58,"coordinates":59},"Point",[60,61],-86.80249,33.52066,{"lat":61,"lon":60},{"facility":50,"status":51,"city":64,"state":65,"zip":66,"country":55,"countryCode":56,"cosmosGeoPoint":67,"geoPoint":71,"contacts":29},"Loma Linda","California","92354",{"type":58,"coordinates":68},[69,70],-117.26115,34.04835,{"lat":70,"lon":69},{"facility":50,"status":73,"city":74,"state":75,"zip":76,"country":55,"countryCode":56,"cosmosGeoPoint":77,"geoPoint":81,"contacts":29},"RECRUITING","Jacksonville","Florida","32216",{"type":58,"coordinates":78},[79,80],-81.65565,30.33218,{"lat":80,"lon":79},{"facility":50,"status":73,"city":83,"state":75,"zip":84,"country":55,"countryCode":56,"cosmosGeoPoint":85,"geoPoint":89,"contacts":29},"Orlando","32808",{"type":58,"coordinates":86},[87,88],-81.37924,28.53834,{"lat":88,"lon":87},{"facility":50,"status":73,"city":91,"state":92,"zip":93,"country":55,"countryCode":56,"cosmosGeoPoint":94,"geoPoint":98,"contacts":29},"Lenexa","Kansas","66219",{"type":58,"coordinates":95},[96,97],-94.73357,38.95362,{"lat":97,"lon":96},{"facility":50,"status":51,"city":100,"state":101,"zip":102,"country":55,"countryCode":56,"cosmosGeoPoint":103,"geoPoint":107,"contacts":29},"Baltimore","Maryland","21201",{"type":58,"coordinates":104},[105,106],-76.61219,39.29038,{"lat":106,"lon":105},{"facility":50,"status":73,"city":109,"state":110,"zip":111,"country":55,"countryCode":56,"cosmosGeoPoint":112,"geoPoint":116,"contacts":29},"Rochester","Minnesota","55905",{"type":58,"coordinates":113},[114,115],-92.4699,44.02163,{"lat":115,"lon":114},{"facility":50,"status":51,"city":118,"state":119,"zip":120,"country":55,"countryCode":56,"cosmosGeoPoint":121,"geoPoint":125,"contacts":29},"San Antonio","Texas","78212",{"type":58,"coordinates":122},[123,124],-98.49363,29.42412,{"lat":124,"lon":123},{"facility":50,"status":51,"city":127,"state":29,"zip":128,"country":129,"countryCode":130,"cosmosGeoPoint":131,"geoPoint":135,"contacts":29},"Chengdu","610072","China","CN",{"type":58,"coordinates":132},[133,134],104.06667,30.66667,{"lat":134,"lon":133},{"facility":50,"status":51,"city":137,"state":29,"zip":138,"country":129,"countryCode":130,"cosmosGeoPoint":139,"geoPoint":143,"contacts":29},"Hangzhou","310003",{"type":58,"coordinates":140},[141,142],120.16142,30.29365,{"lat":142,"lon":141},{"facility":50,"status":51,"city":145,"state":29,"zip":146,"country":129,"countryCode":130,"cosmosGeoPoint":147,"geoPoint":151,"contacts":29},"Nanjing","210009",{"type":58,"coordinates":148},[149,150],118.77778,32.06167,{"lat":150,"lon":149},{"facility":50,"status":51,"city":153,"state":29,"zip":154,"country":129,"countryCode":130,"cosmosGeoPoint":155,"geoPoint":159,"contacts":29},"Shanghai","200025",{"type":58,"coordinates":156},[157,158],121.45806,31.22222,{"lat":158,"lon":157},{"facility":50,"status":51,"city":161,"state":29,"zip":162,"country":129,"countryCode":130,"cosmosGeoPoint":163,"geoPoint":167,"contacts":29},"Wuhan","430022",{"type":58,"coordinates":164},[165,166],114.26667,30.58333,{"lat":166,"lon":165},{"facility":50,"status":51,"city":169,"state":29,"zip":170,"country":129,"countryCode":130,"cosmosGeoPoint":171,"geoPoint":175,"contacts":29},"Xiamen","361101",{"type":58,"coordinates":172},[173,174],118.08187,24.47979,{"lat":174,"lon":173},{"facility":50,"status":73,"city":177,"state":29,"zip":178,"country":179,"countryCode":180,"cosmosGeoPoint":181,"geoPoint":185,"contacts":29},"London","NW3 2QG","United Kingdom","UK",{"type":58,"coordinates":182},[183,184],-0.12574,51.50853,{"lat":184,"lon":183},{"type":187,"investigatorFullName":29,"investigatorTitle":29,"investigatorAffiliation":29,"oldNameTitle":29,"oldOrganization":29},"SPONSOR","100610498","phase-1-safety-tolerability-and-pharmacokinetics-of-azd1613-in-adults-with-autosomal-dominant-polycystic-kidney-disease-100610498",false,"NCT07228364","Safety, Tolerability and Pharmacokinetics of AZD1613 in Adults With Autosomal Dominant Polycystic Kidney Disease","A Phase I Randomised, Single-blind, Placebo-controlled Study to Assess the Safety, Tolerability, and Pharmacokinetics of AZD1613 Following Multiple Ascending Dose Administration in Participants With Autosomal Dominant Polycystic Kidney Disease","PIONEER-PKD","Inclusion Criteria:\n\n* Patients with ADPKD Mayo Class (IB-IE), as per clinical diagnosis (MIC) assessed centrally. Genetic testing results will not be used for eligibility purposes\n* eGFR = 45 to 90 mL\u002Fmin \u002F1.73m2\n* Body weight ≥ 45 kg and body mass index within the range 18 to 35 kg\u002Fm2 (inclusive).\n* Females are to be of non-childbearing potential\n\nExclusion Criteria:\n\n* As judged by the investigator, any evidence of cardiac, vascular, and other renal conditions which in the investigator's opinion makes it undesirable for the participant to participate in the study.\n* Positive hepatitis C antibody, hepatitis B virus surface antigen, or human immunodeficiency virus test, at screening.\n* History of QT prolongation associated with other medications that required discontinuation of that medication.\n* Congenital long QT syndrome.\n* History of ventricular arrhythmia requiring treatment. Patients with atrial fibrillation\u002Fflutter and controlled ventricular rate HR \\\u003C 100 bpm can be eligible as judged by the investigator.\n* Haemoglobin below the lower limit of the normal range or any other clinically significant haematological abnormality as judged by the investigator.\n* Any clinically important abnormalities in clinical chemistry, haematology, coagulation, or urinalysis results other than those specifically described as exclusion criteria herein, as judged by the investigator.\n* Systolic BP \\> 160 mmHg or diastolic BP \\> 100mmHg or HR \\\u003C 50 bpm or \\> 100 bpm at screening. Patients taking anti-hypertensive medication should be on a stable treatment regimen of antihypertensive therapy for at least 30 days prior to the screening visit.\n* Any clinically important abnormalities in rhythm, conduction, or morphology of the resting ECG and any abnormalities in the 12-lead ECG that, as considered by the investigator, may interfere with the interpretation of QTc interval changes, including abnormal ST-T-wave morphology or left ventricular hypertrophy.\n* Kidney cyst interventions such as cyst aspiration or cyst fenestration within 12 weeks prior to screening and during the screening period, or such interventions planned or anticipated within the follow-up period.","ALL","18 Years","65 Years",{"count":200,"type":201},40,"ESTIMATED","INTERVENTIONAL",[204],"PHASE1","A study to investigate safety, tolerability, and pharmacokinetics of AZD1613 following subcutaneous or intravenous administration in participants with autosomal dominant polycystic kidney disease (ADPKD).",[207],"Autosomal Dominant Polycystic Kidney Disease","2026-05-08",{"date":210,"type":211},"2026-05-11","ACTUAL",{"date":213,"type":211},"2025-11-10",{"date":215,"type":201},"2027-01-26",{"name":5,"class":6},15]